ERBB2 and gastroesophageal junction adenocarcinoma: In conclusion, the AGAMENON–SEOM series data, encompassing 1293 patients with advanced HER2-negative esophagogastric adenocarcinoma, reveals that FOLFOX is superior in PFS compared to CP.